Scripta Therapeutics

Scripta Therapeutics is an AI-driven biotech pioneering a novel approach to drug discovery by targeting transcription factors. The company has built a proprietary platform that integrates genome-wide mapping of transcription factors, AI/ML-driven prediction of modulators, and validation in patient-derived models to identify transformative therapeutics. Backed by a consortium of venture capital firms and led by a team with deep pharma, biotech, and computational expertise, Scripta is initially applying its platform to high-unmet-need neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS with the ambition to halt or reverse disease progression.

An AI/ML-driven, closed-loop platform that maps disease-driving transcription factors genome-wide, predicts molecules/targets to modulate them, and validates predictions in patient-derived models.

Scripta competes in the crowded AI/ML drug discovery space, but its specific focus on genome-wide transcription factor mapping and modulation is a key differentiator. It faces competition from both large pharma internal efforts and other biotechs using AI for target discovery, though few are as explicitly centered on transcriptional master regulators.